Immunome Inc

Research Immunome Inc (IMNM) on Bullrun: market cap USD 2.38B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerIMNM
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 2.38B
• Financial periodFY2025
• RevenueUSD 6.94M
• Revenue growth-23.2%
• Net income-USD 212.39M
• Free cash flow-USD 200.60M

Valuation Snapshot

latest market cap is USD 2.38B.

About Immunome Inc

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.

Frequently asked questions

What is Immunome Inc's market cap?

Immunome Inc's market capitalization is USD 2.38B.

What does Immunome Inc do?

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States.